Indian-American's 'super condom' may help combat AIDS

An Indian-American professor and her team has developed a new hydrogel 'supercondom' that can help prevent the spread of the deadly HIV virus that causes AIDS, even after breaking, and also enhance sexual pleasure.
Mahua Choudhery and her team at Texas A&M University in US have come up with the non-latex condom that can not only prevent pregnancy but also help in the global fight against HIV.
The condom is made of an elastic polymer called hydrogel, and includes plant-based antioxidants that have anti-HIV properties.
"We are not only making a novel material for condoms to prevent the HIV infection, but we are also aiming to eradicate this infection if possible," Choudhury, assistant professor at the Texas A&M Health Science Center's Irma Lerma Rangel College of Pharmacy, said.

"Supercondom could help fight against HIV infection and may as well prevent unwanted pregnancy or sexually transmitted diseases and if we succeed, it will revolutionise the HIV prevention initiative," said Choudhury, the lead researcher.
Choudhury, who studied Molecular Biology, Biophysics and Genetics in India before pursuing her PhD in the US, has been researching diabetes and the obesity epidemic.

She was one of 54 people awarded the Bill and Melinda Gates Foundation's "Grand Challenge in Global Health" grant.
This year's initiative asked winning recipients to create an affordable, latex-free condom to help battle the HIV epidemic, which is currently affecting 35 million people in the world.

"If you can make it really affordable, and really appealing, it could be a life-saving thing," Choudhury said.
The condom material already exists as a water-based hydrogel for medical purposes such as contact lenses, researchers said.
In addition to protecting against STDs and pregnancy, researchers enmeshed in the hydrogel design the antioxidant quercetin, which can prevent the replication of HIV and if the condom breaks, the quercetin would be released for additional protection.
Researchers hope the condom will enjoy greater use and have a stronger effect at preventing the spread of HIV as the new design is more comfortable and also heightens sexual pleasure.

The condom has already been created and now the only thing keeping it from going to market is an approval on its patent application, researchers said.
They hope to test the condom within the next six months.
Once released, the new condom will eventually be made available to everyone, including those in rural areas, where these types of resources are limited, Choudhury said.
As part of the scheme, at Valvani's direction, Johnston
obtained highly confidential and material nonpublic information from a senior FDA official about the status and approval of a generic drug called enoxaparin and passed to Valvani.
He used this information to trade in the securities of two pharmaceutical companies likely to be affected by an approval of a generic enoxaparin application, earning approximately USD 25 million in trading profits when the FDA announced its first such approval.

In January 2010, after receiving a tip from Johnston, Valvani told his healthcare-focused hedge fund that Johnston should be given a raise.
In an email to the chief financial officer of the hedge fund, Valvani sought to justify providing a raise to Johnston by stressing how important he was to him: "[Johnston] is without question the most valuable consultant I've ever worked with and I'm pushing to reinforce the value of the relationship and encourage him to continue to go above and beyond for our team."
Valvani surrendered to authorities yesterday morning.
In separate actions, the Securities and Exchange Commission filed civil charges against Valvani, Lumiere, Johnston and Plaford.

"As alleged, Valvani, Johnston, and Plaford conspired to extract highly confidential and tightly guarded information about pending applications for generic drug approvals from the FDA, and traded on such information, reaping millions of dollars in illegal profits," Bharara said.